[go: up one dir, main page]

PT83610A - Process for the preparation of heterocyclic analogs of wevalolactone and derivatives thereofand of pharmaceutical compositions containing them - Google Patents

Process for the preparation of heterocyclic analogs of wevalolactone and derivatives thereofand of pharmaceutical compositions containing them

Info

Publication number
PT83610A
PT83610A PT83610A PT8361086A PT83610A PT 83610 A PT83610 A PT 83610A PT 83610 A PT83610 A PT 83610A PT 8361086 A PT8361086 A PT 8361086A PT 83610 A PT83610 A PT 83610A
Authority
PT
Portugal
Prior art keywords
wevalolactone
thereofand
derivatives
preparation
pharmaceutical compositions
Prior art date
Application number
PT83610A
Other languages
English (en)
Other versions
PT83610B (pt
Inventor
James Richard Wareing
Robert Edson Damon
Original Assignee
Sandoz Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Sa filed Critical Sandoz Sa
Publication of PT83610A publication Critical patent/PT83610A/pt
Publication of PT83610B publication Critical patent/PT83610B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/32—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/33—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms with substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D207/337—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT83610A 1985-10-25 1986-10-23 Processo para a preparacao de analogos heterociclicos de mevalolactona e seus derivados e de composicoes farmaceuticas que os contem PT83610B (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79119885A 1985-10-25 1985-10-25
US81666486A 1986-01-07 1986-01-07

Publications (2)

Publication Number Publication Date
PT83610A true PT83610A (en) 1986-11-01
PT83610B PT83610B (pt) 1989-05-31

Family

ID=27121116

Family Applications (1)

Application Number Title Priority Date Filing Date
PT83610A PT83610B (pt) 1985-10-25 1986-10-23 Processo para a preparacao de analogos heterociclicos de mevalolactona e seus derivados e de composicoes farmaceuticas que os contem

Country Status (12)

Country Link
EP (1) EP0221025A1 (pt)
KR (1) KR900001212B1 (pt)
AU (1) AU598775B2 (pt)
CA (1) CA1278794C (pt)
DK (1) DK321887D0 (pt)
FI (1) FI872299A0 (pt)
HU (1) HUT48208A (pt)
IL (1) IL80403A (pt)
NZ (1) NZ218045A (pt)
PL (1) PL154130B1 (pt)
PT (1) PT83610B (pt)
WO (1) WO1987002662A2 (pt)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647576A (en) * 1984-09-24 1987-03-03 Warner-Lambert Company Trans-6-[2-(substitutedpyrrol-1-yl)alkyl]-pyran-2-one inhibitors of cholesterol synthesis
NO881411L (no) * 1987-04-14 1988-10-17 Bayer Ag Substituerte pyrroler.
US5091378A (en) * 1987-05-22 1992-02-25 E. R. Squibb & Sons, Inc. Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method
DE3722806A1 (de) * 1987-07-10 1989-01-19 Hoechst Ag 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-hept-6-ensaeuren, 7-(1h-pyrrol-3-yl)-substituierte 3,5-dihydroxy-heptansaeuren, ihre entsprechenden (delta)-lactone und salze, verfahren zu ihrer herstellung ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
DE3817808A1 (de) * 1987-07-21 1989-02-02 Bayer Ag Verfahren zur herstellung von 2-substituierten pyrrolen
US4822799A (en) * 1988-01-27 1989-04-18 Sandoz Pharm. Corp. Pyrazolopyridine analogs of mevalonolactone and derivatives thereof useful for inhibiting cholesterol biosynthesis in mammals
NO890988L (no) * 1988-03-24 1989-09-25 Bayer Ag Disubstituerte pyrroler.
EP0339342A1 (de) * 1988-04-23 1989-11-02 Bayer Ag N-Substituierte N-Amino-pyrrole
EP0352575A3 (de) * 1988-07-28 1991-08-21 Bayer Ag Substituierte anellierte Pyrrole
DE3826814A1 (de) * 1988-08-06 1990-02-08 Hoechst Ag Neue 6-fluor-3,5-dihydroxycarbonsaeuren und deren derivate, verfahren zu ihrer herstellung, ihre verwendung als arzneimittel, pharmazeutische praeparate und zwischenprodukte
US5506219A (en) * 1988-08-29 1996-04-09 E. R. Squibb & Sons, Inc. Pyridine anchors for HMG-CoA reductase inhibitors
DE3832570A1 (de) * 1988-09-24 1990-03-29 Hoechst Ag 7-substituierte derivate der 3,5-dihydroxyhept-6-insaeure, verfahren zur ihrer herstellung, ihre verwendung als arzneimittel, sowie zwischenprodukte
IT1237470B (it) * 1988-10-03 1993-06-07 Glaxo Group Ltd Derivati di imidazolo, procedimenti per produrli e composizioni farmaceutiche che li contengono
FI94339C (fi) 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
AU637408B2 (en) * 1989-10-10 1993-05-27 Glaxo Group Limited Substituted N-vinyl imidazole derivatives.
IT1237792B (it) * 1989-12-21 1993-06-17 Zambon Spa Composti attivi come inibitori dell'enzima hmg-coa reduttasi
US5049577A (en) * 1990-01-29 1991-09-17 E. R. Squibb & Sons, Inc. 2-pyrrolidone substituted dihydroxy alkanoic, alkenoic and alkynoic acids, compositions and HMG-CoA reductase inhibition therewith
US5049578A (en) * 1990-03-09 1991-09-17 E. R. Squibb & Sons, Inc. 1-aroyl or 1-acyl-2-2pyrrolidinyl-3,5-dihydroxy alkanoic and alkenoic acids, salts, esters and lactones
US5128366A (en) * 1990-07-05 1992-07-07 Shinogi & Co., Ltd. Pyrrole derivatives
WO1992019240A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Treatment of aberrant cellular states with biomodulators
WO1992019239A1 (en) * 1991-05-01 1992-11-12 University Of New Mexico Treatment of aberrant cellular states with biomodulators
US20010006644A1 (en) 1997-07-31 2001-07-05 David J. Bova Combinations of hmg-coa reductase inhibitors and nicotinic acid and methods for treating hyperlipidemia once a day at night
ES2250182T3 (es) 1999-09-14 2006-04-16 MERCK FROSST CANADA & CO. Acidos carboxilicos y acilsulfonamidas, composiciones que contienen tales compuestos y procedimientos de tratamiento.
EP1216238B1 (en) 1999-09-14 2004-02-18 Merck Frosst Canada & Co. Carboxylic acids and acylsulfonamides, compositions containing such compounds and methods of treatment
US7276249B2 (en) 2002-05-24 2007-10-02 Elan Pharma International, Ltd. Nanoparticulate fibrate formulations
DK1385856T3 (da) 2001-04-11 2006-05-15 Bristol Myers Squibb Co Aminosyrekomplekser af C-aryl-glucosider til behandling af diabetes og fremgangsmåder
US7238671B2 (en) 2001-10-18 2007-07-03 Bristol-Myers Squibb Company Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
KR20040054729A (ko) 2001-10-18 2004-06-25 브리스톨-마이어스 스큅 컴퍼니 인간 글루카곤-유사-펩티드-1 모방체, 및 당뇨병 및 이와관련된 증상의 치료에 있어서 이의 용도
US6806381B2 (en) 2001-11-02 2004-10-19 Bristol-Myers Squibb Company Process for the preparation of aniline-derived thyroid receptor ligands
EP1443919A4 (en) 2001-11-16 2006-03-22 Bristol Myers Squibb Co DOUBLE INHIBITORS OF THE FATTY ACID BINDING PROTEIN OF THE ADIPOCYTES AND THE FATTY ACID BINDING PROTEIN OF KERATINOCYTES
US6831102B2 (en) 2001-12-07 2004-12-14 Bristol-Myers Squibb Company Phenyl naphthol ligands for thyroid hormone receptor
WO2003094845A2 (en) 2002-05-08 2003-11-20 Bristol-Myers Squibb Company Pyridine-based thyroid receptor ligands
JP4533134B2 (ja) 2002-06-10 2010-09-01 エラン ファーマ インターナショナル，リミティド ナノ粒子ポリコサノール製剤および新規なポリコサノールの組合せ
DE60332856D1 (de) 2002-10-23 2010-07-15 Bristol Myers Squibb Co Auf glycinnitril basierende hemmer der dipeptidylpeptidase iv
US7098235B2 (en) 2002-11-14 2006-08-29 Bristol-Myers Squibb Co. Triglyceride and triglyceride-like prodrugs of glycogen phosphorylase inhibiting compounds
WO2004056358A1 (en) 2002-12-20 2004-07-08 Pfizer Products Inc. Dosage forms comprising a cetp inhibitor and an hmg-coa reductase inhibitor
TW200504021A (en) 2003-01-24 2005-02-01 Bristol Myers Squibb Co Substituted anilide ligands for the thyroid receptor
US7557143B2 (en) 2003-04-18 2009-07-07 Bristol-Myers Squibb Company Thyroid receptor ligands
US7459474B2 (en) 2003-06-11 2008-12-02 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
US6995183B2 (en) 2003-08-01 2006-02-07 Bristol Myers Squibb Company Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
US7250444B2 (en) 2003-08-11 2007-07-31 Pfizer Inc. Pyrrole-based HMG-CoA reductase inhibitors
KR20060109926A (ko) 2003-11-19 2006-10-23 메타베이시스 테라퓨틱스, 인크. 새로운 인-함유 갑상선 호르몬 모방약들
US8158362B2 (en) 2005-03-30 2012-04-17 Decode Genetics Ehf. Methods of diagnosing susceptibility to myocardial infarction and screening for an LTA4H haplotype
WO2005087234A1 (en) 2004-03-05 2005-09-22 The Trustees Of The University Of Pennsylvania Methods for treating disorders or diseases associated with hyperlipidemia and hypercholesterolemia while minimizing side-effects
TW200611704A (en) 2004-07-02 2006-04-16 Bristol Myers Squibb Co Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
US7145040B2 (en) 2004-07-02 2006-12-05 Bristol-Myers Squibb Co. Process for the preparation of amino acids useful in the preparation of peptide receptor modulators
US7534763B2 (en) 2004-07-02 2009-05-19 Bristol-Myers Squibb Company Sustained release GLP-1 receptor modulators
AR051446A1 (es) 2004-09-23 2007-01-17 Bristol Myers Squibb Co Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2)
US7517991B2 (en) 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
US7589088B2 (en) 2004-12-29 2009-09-15 Bristol-Myers Squibb Company Pyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
US7635699B2 (en) 2004-12-29 2009-12-22 Bristol-Myers Squibb Company Azolopyrimidine-based inhibitors of dipeptidyl peptidase IV and methods
WO2006076598A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
US7368458B2 (en) 2005-01-12 2008-05-06 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
WO2006076568A2 (en) 2005-01-12 2006-07-20 Bristol-Myers Squibb Company Thiazolopyridines as cannabinoid receptor modulators
WO2006078697A1 (en) 2005-01-18 2006-07-27 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid receptor modulators
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
US7521557B2 (en) 2005-05-20 2009-04-21 Bristol-Myers Squibb Company Pyrrolopyridine-based inhibitors of dipeptidyl peptidase IV and methods
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
US7632837B2 (en) 2005-06-17 2009-12-15 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoid-1 receptor modulators
US7629342B2 (en) 2005-06-17 2009-12-08 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
US7317012B2 (en) 2005-06-17 2008-01-08 Bristol-Myers Squibb Company Bicyclic heterocycles as cannabinoind-1 receptor modulators
TW200726765A (en) 2005-06-17 2007-07-16 Bristol Myers Squibb Co Triazolopyridine cannabinoid receptor 1 antagonists
AR056155A1 (es) 2005-10-26 2007-09-19 Bristol Myers Squibb Co Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
WO2007053819A2 (en) 2005-10-31 2007-05-10 Bristol-Myers Squibb Company Pyrrolidinyl beta-amino amide-based inhibitors of dipeptidyl peptidase iv and methods
US7592461B2 (en) 2005-12-21 2009-09-22 Bristol-Myers Squibb Company Indane modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
US7553836B2 (en) 2006-02-06 2009-06-30 Bristol-Myers Squibb Company Melanin concentrating hormone receptor-1 antagonists
US8367112B2 (en) 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
EP2021014A1 (en) 2006-05-26 2009-02-11 Brystol-Myers Squibb Company Sustained release glp-1 receptor modulators
US7919598B2 (en) 2006-06-28 2011-04-05 Bristol-Myers Squibb Company Crystal structures of SGLT2 inhibitors and processes for preparing same
US7968577B2 (en) 2006-11-01 2011-06-28 Bristol-Myers Squibb Company Modulators of glucocorticoid receptor, AP-1, and/or NF-κB activity and use thereof
TW200904405A (en) 2007-03-22 2009-02-01 Bristol Myers Squibb Co Pharmaceutical formulations containing an SGLT2 inhibitor
PE20090696A1 (es) 2007-04-20 2009-06-20 Bristol Myers Squibb Co Formas cristalinas de saxagliptina y procesos para preparar las mismas
US20090011994A1 (en) 2007-07-06 2009-01-08 Bristol-Myers Squibb Company Non-basic melanin concentrating hormone receptor-1 antagonists and methods
WO2009018065A2 (en) 2007-07-27 2009-02-05 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
EP2197873B1 (en) 2007-09-20 2014-07-16 Irm Llc Compounds and compositions as modulators of gpr119 activity
PE20091928A1 (es) 2008-05-29 2009-12-31 Bristol Myers Squibb Co Tienopirimidinas hidroxisustituidas como antagonistas de receptor-1 de hormona concentradora de melanina no basicos
US20120046364A1 (en) 2009-02-10 2012-02-23 Metabasis Therapeutics, Inc. Novel Sulfonic Acid-Containing Thyromimetics, and Methods for Their Use
BRPI1013500A2 (pt) 2009-03-27 2016-04-05 Astrazeneca Uk Ltd métodos para previnir eventos cardiovasculares adversos maiores com inibidores de dpp-iv
WO2011014520A2 (en) 2009-07-29 2011-02-03 Irm Llc Compounds and compositions as modulators of gpr119 activity
BR112012008004A2 (pt) 2009-10-09 2016-03-29 Irm Llc compostos e composições como moduladores da atividade de gpr119
BR112012011726A2 (pt) 2009-11-13 2020-05-19 Bristol-Myers Squibb Company comprimidos de duas camadas, seu uso, e suas combinações farmacêuticas
JP5784623B2 (ja) 2009-11-13 2015-09-24 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 速放性錠剤製剤
JP5798123B2 (ja) 2009-11-13 2015-10-21 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 低質量のメトホルミン製剤
US8394858B2 (en) 2009-12-03 2013-03-12 Novartis Ag Cyclohexane derivatives and uses thereof
TWI562775B (en) 2010-03-02 2016-12-21 Lexicon Pharmaceuticals Inc Methods of using inhibitors of sodium-glucose cotransporters 1 and 2
EP2558461B1 (en) 2010-04-14 2015-12-02 Bristol-Myers Squibb Company Novel glucokinase activators and methods of using same
WO2012006398A2 (en) 2010-07-09 2012-01-12 Bhv Pharma, Inc. Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
US8697739B2 (en) 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
TWI631963B (zh) 2011-01-05 2018-08-11 雷西肯製藥股份有限公司 包含鈉－葡萄糖共同輸送體１與２之抑制劑的組合物與應用方法
WO2014052619A1 (en) 2012-09-27 2014-04-03 Irm Llc Piperidine derivatives and compositions as modulators of gpr119 activity
DK3489226T3 (da) 2012-11-20 2021-04-26 Lexicon Pharmaceuticals Inc Hæmmere for natriumglucose-cotransporter 1
US9593113B2 (en) 2013-08-22 2017-03-14 Bristol-Myers Squibb Company Imide and acylurea derivatives as modulators of the glucocorticoid receptor
EP3191098A4 (en) 2014-09-12 2018-04-25 G1 Therapeutics, Inc. Combinations and dosing regimes to treat rb-positive tumors
MX2017013807A (es) 2015-04-30 2018-03-15 Harvard College Anticuerpos anti-proteina de union al lipido de adipocito humana (ap2) y agente de union al antigeno para tratar trastornos metabolicos.
AU2019304032B2 (en) 2018-07-19 2021-12-09 Astrazeneca Ab Methods of treating HFpEF employing dapagliflozin and compositions comprising the same
EP3856714A1 (en) 2018-09-26 2021-08-04 Lexicon Pharmaceuticals, Inc. Crystalline forms of n-(1 -((2-(dimethylamino)ethyl)amino)-2-m ethyl-1 -oopropan-2-yl)-4-(4-(2-methyl-5- (2s,3r,4r,5s,6r)-3,4,5-trihydroxy-6-(methylthio)tetrahydro-2h-pyran-2-yl)benzyl) phenl)butanamide and methods of their synthesis
CN116322682A (zh) 2020-07-29 2023-06-23 艾米琳制药有限责任公司 在治疗儿科患者的高脂血症和高胆固醇血症的方法中使用的洛美他派
WO2025147589A1 (en) 2024-01-05 2025-07-10 Osanni Bio, Inc. Implants, compositions, and methods for treating retinal diseases and disorders

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3168527A (en) * 1962-06-14 1965-02-02 Parke Davis & Co 1-aryl-5-(p-fluorophenyl)-pyrrole-2-propionic acid compounds
US3168532A (en) * 1963-06-12 1965-02-02 Parke Davis & Co 1, 5-diarylpyrrole-2-propionic acid compounds
US3462451A (en) * 1966-04-25 1969-08-19 Upjohn Co 2,3-bis(alkoxyphenyl)pyrroles
DE2261965A1 (de) * 1971-12-23 1973-06-28 Continental Pharma Derivate der pyrrolessigsaeure und deren salze sowie von pyrrolacetonitril, verfahren zur herstellung dieser verbindungen, diese verbindungen enthaltende pharmazeutische produkte und verwendung dieser verbindungen und produkte
US4035394A (en) * 1976-02-24 1977-07-12 Morton-Norwich Products, Inc. 5-Phenyl-2-furanyl-oxo or-hydroxy alkanoic acids and ethyl esters as gastric acid antisecretory agents
HU187137B (en) * 1982-06-22 1985-11-28 Richter Gedeon Vegyeszet Process for producing esters of 1-alkyl- orl,4-dialkyl-1h-pyrrol-acetic acid
WO1984002131A1 (fr) * 1982-11-22 1984-06-07 Sandoz Ag Produits analogues de mevalolactone et leurs derives, leurs procedes de production, compositions pharmaceutiques les contenant ainsi que leur utilisation en tant que produits pharmaceutiques
DE3461180D1 (en) * 1983-01-24 1986-12-11 Sandoz Ag Analogs of mevalonolactone and derivatives thereof, processes for their production, pharmaceutical compositions containing them and their use as pharmaceuticals
DE3309355A1 (de) * 1983-03-16 1984-09-27 Basf Ag, 6700 Ludwigshafen Verfahren zur herstellung von pyrrolen
DE3407510A1 (de) * 1984-03-01 1985-09-05 A. Nattermann & Cie GmbH, 5000 Köln (omega)-aryl-alkylthienylalk(a,e)nsaeuren und ihre derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate
AU573368B2 (en) * 1984-06-22 1988-06-02 Sandoz Ag Pyrazole analogs of mevalonolactone and derivatives thereof, process for their production and their use
AU599580B2 (en) * 1984-12-04 1990-07-26 Sandoz Ag Indene analogs of mevalonolactone

Also Published As

Publication number Publication date
KR870700602A (ko) 1987-12-30
KR900001212B1 (ko) 1990-02-28
IL80403A0 (en) 1987-01-30
FI872299A7 (fi) 1987-05-25
PL154130B1 (en) 1991-07-31
PT83610B (pt) 1989-05-31
EP0221025A1 (en) 1987-05-06
IL80403A (en) 1990-09-17
NZ218045A (en) 1990-03-27
DK321887A (da) 1987-06-24
HUT48208A (en) 1989-05-29
CA1278794C (en) 1991-01-08
AU6599486A (en) 1987-05-19
AU598775B2 (en) 1990-07-05
WO1987002662A3 (en) 1987-12-17
WO1987002662A2 (en) 1987-05-07
DK321887D0 (da) 1987-06-24
FI872299A0 (fi) 1987-05-25
PL262032A1 (en) 1988-07-21

Similar Documents

Publication Publication Date Title
PT83610A (en) Process for the preparation of heterocyclic analogs of wevalolactone and derivatives thereofand of pharmaceutical compositions containing them
HUT42101A (en) Process for preparing stomatostatine derivatives and pharmaceutical compositions containing such compounds
PT82030A (en) Process for the preparation of 4-substituted androstendione derivatives and of pharmaceutical compositions containing the same
PT82810A (en) Process for the preparation of new piperazine derivatives and of pharmaceutical compositions containing the same
PT81015B (en) Process for the preparation of piridazo-diazocine derivatives and pharmaceutical compositions therewith
PT85071A (en) Process for the preparation of derivatives of fused cyclic azepin-2-ones and of pharmaceutical compositions containing the same
PT86516A (en) Process for the preparation of heteroaryl-3-oxo-propani-nitrile derivatives and of pharmaceutical compositions containing the same
PT86365A (en) Process for the preparation of pyridazodiazepine derivatives and of pharmaceutical compositions containing the same
PT82294B (en) Process for the preparation of arylethanolamine derivatives and of pharmaceutical compositions containing the same
PT83495A (en) Process for the preparation of n-substituted diphenylpiperidines and of pharmaceutical compositions containing the same
PT82984A (en) Process for the preparation of poly-4-aminopyrrole-2-carboxamido derivatives and of pharmaceutical compositions containing the same
PT80246A (en) Process for the preparation of novel cephalosporin derivatives and of pharmaceutical compositions containing the same
PT82121B (en) Process for the preparation of novel aromatic heterocyclic acid derivatives and of pharmaceutical compositions containing the same
PT83604A (en) Process for the preparation of flavone derivatives and of pharmaceutical compositions containing the same
PT83565A (en) Process for the preparation of acid aryl-heterocyclic-alcoxi-acetic derivatives and of pharmaceutical compositions containing same
PT83188A (en) Process for the preparation of benzimidazole derivatives and of pharmaceutical compositions containing the same
PT82395B (en) Process for the preparation of synthetic derivatives of pseudopterosin and of pharmaceutical compositions containing the same
PT82523A (en) Process for the preparation of antipsychotic fused-ring pyridinylpiperazine derivatives and of pharmaceutical compositions containing the same
PT77694A (en) Process for the preparation of mevalono lactone analogs and their derivatives and pharmaceutical compositions containing them
PT82772A (en) Process for the preparation of novel glycerol derivatives and of pharmaceutical compositions containing the same
PT82960A (en) Process for preparing 5-substituted-6-amino-pyrimidine derivatives and pharmaceutical compositions containing them
PT83305A (en) Process for the preparation of xanthine derivatives and pharmaceutical compositions containing them
HU895952D0 (en) Process for the preparation of substituted pyrrolidone-2-carboxylic acid derivatives and pharmaceutical compositions containing them
PT82464A (en) Process for the preparation of novel benzisoselenazolonyl derivatives and of pharmaceutical compositions containing the same
PT81084A (en) Process for the preparation of new 6-substituted mitomycin analogs and of pharmaceutical compositions containing the same

Legal Events

Date Code Title Description
MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 19920531